Lee Ainslie Gilead Sciences, Inc. Transaction History

Maverick Capital LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $622,200 - $709,930	-10,370 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $1.98 Million - $2.26 Million	-35,010 Reduced 77.15%	10,370 $604,000
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $2.82 Million - $3.54 Million	45,380 New	45,380 $2.87 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $1.59 Million - $2.03 Million	-25,365 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $567,212 - $623,914	9,205 Added 56.96%	25,365 $1.65 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $1.01 Million - $1.12 Million	16,160 New	16,160 $1.02 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.